Germany extends drug price caps; Doc convicted of selling foreign cancer meds; India's drug market lags;

@FiercePharma: Top new news Thursday: Bristol bails out of diabetes venture in $4.1B sell-out to AstraZeneca. More | Follow @FiercePharma

@EricPFierce: FDA still has to approve J&J plans to lease part of Ben Venue plant and make Doxil itself. Article | Follow @EricPFierce

@CarlyHFierce: Bad news for AstraZeneca. Appeals court frees Hanmi of double-damage risk for its Nexium copy. Story | Follow @CarlyHFierce

> Germany has extended its price freeze on drugs, which capped them at 2009 price levels, through March of next year. Story

> Canada-based Nuvo Research has an agreement for Russian pharmaceutical company NovaMedica to distribute its osteoarthritis treatments Pennsaid 1.5% and Pennsaid 2% in Russia. Release

> Forest Laboratories' ($FRX) Fetzima, which the FDA approved in July for treatment of major depressive disorder (MDD), is now available in pharmacies in the U.S. Release

> Effective January 1, 2014,  Astellas Pharma's Astagraf XL for kidney transplant patients will have a unique product-specific CMS code, which will remove reimbursement issues associated with providers submitting a miscellaneous code. Release

> A jury convicted a 65-year-old doctor, Anindya Kumar Sen, M.D., and his wife and office manager, Patricia Posey Sen, 66, of buying and using foreign-made cancer drugs in their oncology practice, East Tennessee Cancer and Blood Center. Release

Medical Device News

@FierceMedDev: Baxter nails a CE mark for next-generation home hemodialysis. More | Follow @FierceMedDev

@MarkHFierce: More problems for 23andMe--two women are suing the company over its test claims. Article | Follow @MarkHFierce

@MichaelGFierce: 'Walking' DNA motor on nanotube tracks could someday deliver drugs. More from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: FDA approves Philips' spectrometry for dense breasts in cancer screenings. Story | Follow @GalenMoore

> IPOs, M&A and the Supreme Court filled out a heady year for med tech. Editor's corner

> Vermillion secures $17.6M to expand push for ovarian cancer Dx. News

> AtriCure grabs ablation device maker Estech for $34M. More

Biotech News

@FierceBiotech: The 5 biggest trends in biopharma R&D in 2013. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: J&J partners up with Orion on a new approach to fighting Alzheimer's--neurotransmitters--a la Lundbeck/Otsuka. News | Follow @JohnCFierce

@DamianFierce: Welcome back, Iclusig. Release | Follow @DamianFierce

@EmilyMFierce: Cells from the eye are inkjet printed for the first time. More | Follow @EmilyMFierce

> Ariad storms back with an FDA nod to get Iclusig back on the U.S. market. Story

> GlycoMimetics gets back on the IPO train with another pitch. More

> Jazz Pharma trades $1B for Gentium and a well-traveled orphan drug. News

And Finally... Growth in India's domestic drugs market slowed to 9.8% this year, down from 16.6% percent in 2012 as price controls made a dent. Story

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.